Background
Relapsed/refractory follicular lymphoma after multiple lines, particularly POD24 disease, has poor outcomes. ELARA was a pivotal phase II single-arm trial of tisagenlecleucel (tisa-cel), an autologous anti-CD19 CAR-T, in r/r FL after ≥2 prior lines including an anti-CD20 regimen.
Interventions and follow up
Regimen: Tisagenlecleucel single infusion (0.6–6 × 10⁸ CAR-positive viable T cells) after lymphodepleting chemotherapy (fludarabine + cyclophosphamide); bridging chemotherapy permitted
Population: N=97 infused (94 evaluable), r/r FL, ≥2 prior lines
Primary endpoint: complete response rate by independent review (modified Lugano)
Median follow-up: 16.6 months (primary analysis)
Population: N=97 infused (94 evaluable), r/r FL, ≥2 prior lines
Primary endpoint: complete response rate by independent review (modified Lugano)
Median follow-up: 16.6 months (primary analysis)
Results
Complete response rate: 69.1% (95% CI 58.8–78.3)
Overall response rate: 86.2% (95% CI 77.5–92.4)
Duration of response / PFS: median DoR not reached; estimated 24-month PFS ~68%
Subgroups: responses consistent in high-risk subsets (POD24, transformed FL, prior ASCT)
Overall response rate: 86.2% (95% CI 77.5–92.4)
Duration of response / PFS: median DoR not reached; estimated 24-month PFS ~68%
Subgroups: responses consistent in high-risk subsets (POD24, transformed FL, prior ASCT)
Adverse events
CRS: any grade 48.5%, Grade ≥3 0%
ICANS/neurologic: any grade ~9-37%, Grade ≥3 ~3%
Hematologic: Grade ≥3 cytopenias common; prolonged neutropenia in ~25%
Other: no treatment-related deaths; absence of Grade ≥3 CRS distinguishes tisa-cel from axi-cel
ICANS/neurologic: any grade ~9-37%, Grade ≥3 ~3%
Hematologic: Grade ≥3 cytopenias common; prolonged neutropenia in ~25%
Other: no treatment-related deaths; absence of Grade ≥3 CRS distinguishes tisa-cel from axi-cel
Conclusions
Tisagenlecleucel achieved high, durable complete responses with a manageable safety profile in heavily pretreated r/r FL, including high-risk POD24 patients, establishing CAR-T as an effective third-line-plus option.
Key Limitations
Single-arm design without randomized comparator; no head-to-head with other 3L+ options (tazemetostat, lenalidomide-rituximab, bispecifics); long-term durability still maturing; manufacturing failure ~4%; variable bridging-therapy effects; logistics and cost remain real-world barriers.
Clinical Context
ELARA led to FDA approval of tisagenlecleucel for r/r FL (3L+) in May 2022; EMA followed. Axicabtagene ciloleucel (ZUMA-5) is also approved with higher CR but more CRS/neurotoxicity. Bispecific antibodies (mosunetuzumab, epcoritamab) offer outpatient alternatives or bridges to CAR-T.